PAREXEL EXPANDS ITS NORTH AMERICAN MEDICAL SERVICES DIVISION
BOSTON, MA, September 4, 2001 — PAREXEL International Corporation (Nasdaq: PRXL) today announced the addition of two new scientific leaders to the North American Medical Services (NAMS) Division. Alicia Rossiter, M.D. joins NAMS as Associate Medical Director and Head of Pharmacovigilance. She is based in Boston. Dr. Rossiter assumes responsibility for the management and performance of safety surveillance for approved products. Guillermo Rossiter, M.D. will serve as Associate Medical Director, specializing in Gastroenterology and Internal Medicine. He is also based in Boston.
Dr. Alicia Rossiter obtained her medical degree at the Universidad Central de Venezuela. She completed a Clinical Pharmacology fellowship at Harvard University in 1991 and was appointed Fellow of the American College of Clinical Pharmacology in 1993. Previous positions held by Dr. Rossiter include appointments at the National Institute of Hygiene in Venezuela, as Reviewer Physician for drug approval, and Medical Director at Smithkline Beecham (now GlaxoSmithKline) in Venezuela. Additionally, Dr. Rossiter participated in the early stages of the creation of the National Center for Drug Surveillance in Venezuela.
In addition to Dr. Alicia Rossiter, PAREXEL gains Dr. Guillermo Rossiter as a scientific resource. He received his medical degree at the Universidad de Carabobo, Venezuela. Dr. Rossiter completed a three-year Fellowship in Medicine at Harvard University, and later a Fellowship at the Massachusetts General Hospital Gastrointestinal Unit. In 1999, Dr. Rossiter was a Visiting Endoscopy Fellow at the Brigham & Women’s Hospital. During his medical career, Dr. Rossiter has acquired wide experience in basic and clinical research, academic teaching, pharmaceutical industry, and medical communications. Extensively published in medical journals, Dr. Rossiter obtained the National Award of Gastroenterology in Venezuela in 1992. Important appointments held by Dr. Rossiter include Medical Director of Laboratorios Vargas, the largest domestic pharmaceutical company in Venezuela. Prior to joining PAREXEL, Dr. Rossiter worked as an attending Gastroenterologist at the Hospital General del Oeste and Centro Medico de Caracas, Venezuela.
“The expertise of the Rossiters augments PAREXEL’s knowledge base in medicine and drug safety to the benefit of our clients,” stated Jonathan M. Fishbein, M.D., Vice President of North American Medical Services. “Their knowledge and experience in South America will enhance our drug safety operation by facilitating the surveillance of adverse drug effects throughout the western hemisphere.”
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 54 locations throughout 35 countries around the world, and has approximately 4,695 Employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended March 31, 2001, as filed with the Securities and Exchange Commission.